Glioma
is the most prevalent type of malignant brain tumor and
is usually very aggressive. Because of the high invasiveness and aggressive
proliferative growth of glioma, it is difficult to resect completely
or cure with surgery. Residual glioma cells are a primary cause of
postoperative recurrence. Herein, we describe a hypoxia-responsive
lipid polymer nanoparticle (LN) for fluorescence-guided surgery, chemotherapy,
photodynamic therapy (PDT), and photothermal therapy (PTT) combination
multitherapy strategies targeting glioma. The hypoxia-responsive LN
[LN (DOX + ICG)] contains a hypoxia-responsive component poly(nitroimidazole)25 [P-(Nis)25], the glioma-targeting peptide angiopep-2
(A2), indocyanine green (ICG), and doxorubicin (DOX). LN (DOX + ICG)
comprises four distinct functional components: (1) A2: A2 modified
nanoparticles effectively target gliomas, enhancing drug concentration
in gliomas; (2) P-(Nis)25: (i) the hydrophobic component
of LN (DOX + ICG) with hypoxia responsive ability to encapsulate DOX
and ICG; (ii) allows rapid release of DOX from LN (DOX + ICG) after
808 nm laser irradiation; (3) ICG: (i) ICG allows imaging-guided surgery,
combining PDT and PTT therapies; (ii) upon irradiation with an 808
nm laser, ICG creates a hypoxic environment; (4) DOX inhibits glioma
growth. This work demonstrates that LN (DOX + ICG) might provide a
novel clinical approach to preventing post-surgical recurrence of
glioma.